ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives

Table 1

Studies investigating the incidence of leukemia and all hematopoietic tumours in AAVs.

	Knight et al. 2002 [62]	Faurschou et al. 2008 [63]	Holle et al. 2011 [64]	Heijl et al. 2011 [65]	Zycinska et al. 2013 [66]	Faurschou et al. 2015 [67]	Rahmattulla et al. 2015 [68]	van Daalen et al. 2017 [33]	Sriskandarajah et al. 2017 [69]	Heaf et al. 2018 [70]	Yoo et al. 2018 [46]
SIR of leukemia (95% CI)	5.7 (2.3–12)	5.9 (1.2-17)	Not statistically increased	3.2 (0.4-11.7)	4.3 (2.1-11.2)	13.3 (3.6-34)	Not Statistically increased	Not statistically increased	—		Not statistically increased
Observed minus expected leukemia cases (%) if significant	—	—	—	—	—	—	—	—	—	11	—
SIR of all hematopoietic tumours (95% CI)	3.8 (2.1–6.3)	—	—	—	—	1.9 (0.5–5.0)	Not statistically increased	Not statistically increased	3.52 (1.32–9.37)	—	Not statistically increased
Study period	1969-1994	1973-1999	1966-2002	1995-2002	1990-2008	1973-1999	1991-2013	2000-2014	1988-2012	1985-2015	—
Patient number	1065	293	290	535	117	293	138	323	419	278	150
Patient composition	GPA only	GPA only	GPA only	AAV	AAV	GPA only	AAV	AAV	AAV	AAV	AAV
Country	Sweden	Denmark	Germany	Europe, Mexico	Poland	Denmark	Netherlands	Europe	Norway	Denmark	Korea
Data collection	National study	National study	Single-center study	Multicenter study	Single-center study	National study	Single-center study	Single-center study	National study	National study	Single-center study